14
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efectos metabólicos de la asociación glibenclamida-metformín en diabéticos obesos

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          La asociación de hidrocloruro de metformín y sulfonilureas ha sido utilizada en pacientes en los que no se logra un control con sulfonilureas como monoterapia. En el presente trabajo se evaluó el efecto de la combinación de metformín y glibenclamida sobre la glicemia, colesterolemia y trigliceridemia en pacientes diabéticos obesos no insulinodependientes de difícil control. Se encontró que se producía un control de la glicemia a partir de los 2 meses de tratamiento, así como disminución de la colesterolemia y trigliceridemia luego de 2 meses de tratamiento. Se concluye que la terapéutica utilizada fue útil en el control de pacientes diabéticos obesos con resistencia a la glibenclamida.

          Translated abstract

          The association of metformin hydrochloride with sulphonylureas has been used when it is not possible to control the patient with sulphonylureas as a monotherapy. In the present paper it was evaluated the effect of the combination of metformin and glibenclamide on glycemia, cholesterolaemia and triglyceridemia in non-insuline dependent obese diabetic patients hard to control. There was a control of glycemia as well as a reduction of cholesterolaemia and triglyceridemia after the second month of treatment. It is concluded that the therapeutics used was useful to control obese diabetic patients resistant to glibenclamide.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: not found
          • Article: not found

          Oral hypoglycemic agents.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus.

            The effects of metformin on glycaemia, insulin and c-peptide levels, hepatic glucose production and insulin sensitivity (using the euglycaemic, hyperinsulinaemic clamp) were evaluated at fortnightly intervals in 9 Type 2 diabetic patients using a stepwise dosing protocol: Stage 1--no metformin for four weeks; stage 2--metformin 500mg mane; stage 3--metformin 500mg thrice daily; stage 4--metformin 1000mg thrice daily. Results are expressed as Mean +/- SEM. Fasting blood glucose decreased from basal values (9.7 +/- 1.0 mmol/L) by 13% at stage 2, 34% at stage 3 and 41% at stage 4 (p less than 0.02 vs basal for all stages; p less than 0.02 stage 2 vs stage 3). Post-prandial glycaemia was significantly improved only with metformin 3000mg/day (p less than 0.05). Fasting, meal-stimulated and total insulin and c-peptide levels showed no change. Hepatic glucose output did not change significantly with metformin. Insulin sensitivity, measured as total glucose utilisation during hyperinsulinaemia, increased from stage 1 (10.3 +/- 2.1 mumoL/kg/min) by 23% at stage 3 (p less than 0.05) and by 29% at stage 4 (p less than 0.02). Basal metabolic clearance of glucose increased compared to stage 1 (1.69 +/- 0.16 mL/kg/min) by 30% at stage 2, 53% at stage 3 and 44% at stage 4 (all p less than 0.02). This study demonstrates that improved efficiency of glucose utilisation, both basally and under conditions of euglycaemic hyperinsulinaemia, is the basis of metformin's antihyperglycaemic action.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Biguanides and sulfonylureas as combination therapy in NIDDM.

              L Hermann (1990)
              Oral combination therapy with biguanides (metformin) and sulfonylureas is discussed. The rationale for the use of this combination is based on the different sites of action of the two kinds of drugs and the possibility for obtaining additive or potentiating effects and reduced side effects. The clinical usefulness of chlorpropamide and glyburide in combination with metformin has been demonstrated in some clinical trials. The combination may provide satisfactory glycemic control for several years, and possibly insulin therapy can be postponed or even avoided. No special safety problems are encountered with the use of the combination other than those attributed to the use of metformin or sulfonylurea alone, i.e., lactic acidosis and hypoglycemia, respectively. The lethality risks of these associated conditions are comparable. It is concluded that more data are needed to evaluate the full clinical potential and the mechanism of action of oral combination therapy.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                ibi
                Revista Cubana de Investigaciones Biomédicas
                Rev Cubana Invest Bioméd
                ECIMED (Ciudad de la Habana )
                1561-3011
                June 1997
                : 16
                : 1
                : 55-58
                Article
                S0864-03001997000100009
                c0daeb9b-b3a5-4624-9c29-8d4ce02ed17c

                http://creativecommons.org/licenses/by/4.0/

                History
                Product

                SciELO Cuba

                Self URI (journal page): http://scielo.sld.cu/scielo.php?script=sci_serial&pid=0864-0300&lng=en
                Categories
                MEDICINE, RESEARCH & EXPERIMENTAL

                Medicine
                DIABETES MELLITUS, NON-INSULIN DEPENDENT,OBESITY IN DIABETES,GLYBURIDE,METFORMIN,BLOOD GLUCOSE,TRIGLYCERIDES,CHOLESTEROL,DRUG THERAPY, COMBINATION,DIABETES MELLITUS NO INSULINO-DEPENDIENTE,OBESIDAD EN DIABETES,GLIBURIDA,METFORMINA,GLUCOSA DE LA SANGRE,TRIGLICERIDOS,COLESTEROL,QUIMIOTERAPIA COMBINADA

                Comments

                Comment on this article